Blog
Filter blogs by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category.
-
EU CTR: Practical experiences and lessons learned
EU CTR effective January 31, 2022, introducing new age for interventional clinical trial applications in EU and EEA. Read more about the practical experiences and lessons learned.
-
Rare diseases and orphan drugs regulatory framework in Canada
This blog details initiatives that are being taken by the Government of Canada to promote a health care system that works for those with rare disorders.
-
The impact of the new EU Clinical Trial Regulation on language translation
On January 31st, 2023, the EU Clinical Trial Regulation and the Clinical Trial Information System went live and changed the European landscape for clinical trials.
-
.jpg?crop=yes&w=210&h=209&itok=a2Kv7gUg "Boardroom Meeting (38).jpg")
Biotech’s evolving relationship with CROs
In this blog, read more on recent trends and learn why strategic outsourcing is a key opportunity.
-
Recent trends in the biotech funding environment
In this blog, discover more about how the biotech sector is transforming uncertainty into opportunity.
-
Improving the experience of healthy volunteers during early phase clinical trials
How ICON’s application of a volunteer-centric approach is improving recruitment and retention rates of healthy participants in early phase studies.
-
Pre-emptive vaccine research to improve EID response
This blog explores strategies for strengthening vaccine development so that the medical community is better prepared to respond to future epidemics.
-
Use of ddPCR and qPCR assays for PK and safety monitoring in Cell & Gene Therapy clinical trials
Immunotherapy technologies are rapidly advancing, as are the methods of ensuring their safety and reliability. ICON explores the tools used in CGT trials.
-
From clinician visits to data analysis: the challenges and solutions in COVID vaccine pharmacovigilance
Learn more about the challenges and solutions in assessing the long-term effects of Covid and Covid vaccines in this blog.
-
Mary O’Reilly reflects on International Women’s Day
In this blog, Mary O’Reilly reflects on the International Women’s Day panel and events held at ICON’s global headquarters in Dublin.
-
How data science is changing the face of healthcare
In this podcast, Michael Goedde shares his journey in technology and his role in building the digital platform for healthcare systems at ICON.
-
A positive step for diversity and inclusion in clinical trials – reflections on FDORA
Read this blog for updated recommendations and additional guidance on DCTs to ensure equitable access to cutting-edge therapeutics and clinical trials.
-
Rare Disease Day diversity and inclusion
This event aims to raise awareness about the diversity of individuals affected by rare diseases. Find out how virtual events can be made more accessible and inclusive.
-
-
My patient story - Claudia Egremont-Lee
ICON's Claudia Egremont-Lee shares her personal experience with breast cancer.
-
My patient story - Margaritte De Falco
ICON's Margaritte De Falco shares her personal experience with ovarian cancer.
-
The importance of developing rTPP to build biotech asset value
Discover how Biotechs can build value into their asset by developing a reimbursable Target Product Profile (rTPP).
-
The impact of real world evidence on drug marketing approval and reimbursement
Increasing use of real world data and real world evidence for market regulatory decisions can lead to a more holistic understanding of safety and potency factors for healthcare practices.
-
Redefining sourcing model terminology
This blog explores the new framework for defining CRO sourcing models and explains its importance.
-
Optimising biotech trial designs to stretch your cash runway
Read this blog to learn a few key considerations to help optimise and de-risk your trial design.